acetylgalactosamine has been researched along with Porphyrias, Hepatic in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 12 (92.31) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, S; Clausen, VA; Harper, P; Najafian, N; Robbie, GJ; Sardh, E; Simon, AR; Vassiliou, D | 1 |
| Aguilera-Peiró, P; Anderson, DKE; Balwani, M; Bonkovsky, HL; Gouya, L; Hua, Z; Ko, JJ; Kuter, DJ; Monroy, S; Montgomery Bissell, D; Oh, J; Parker, C; Ritchie, B; Sardh, E; Stein, PE; Sweetser, MT; Ventura, P | 1 |
| Harper, P; Sardh, E | 1 |
| Ricci, A; Ventura, P | 1 |
| Bonkovsky, HL; Ma, CD; Majeed, CN; Rudnick, S; Xiao, T | 1 |
| Scott, LJ | 1 |
| Bonkovsky, HL; Honor, A; Rudnick, SR | 1 |
| Syed, YY | 1 |
| Holm, A; Kauppinen, S; Løvendorf, MB | 1 |
| Arciprete, M; Chong, S; Clausen, V; Guan, LH; Li, J; Liu, J; Najarian, D; Rocca, C; Smith, P; Tran, C; Wang, Q; Wu, JT; Xu, Y; Zhang, G; Zhang, X | 1 |
| Agarwal, S; Aluri, K; Arciprete, M; Brown, C; Castellanos-Rizaldos, E; Charisse, K; Chong, S; Cichocki, J; Fitzgerald, K; Goel, V; Gu, Y; Guenther, D; Habtemariam, B; Jadhav, V; Janas, M; Jayaraman, M; Kurz, J; Li, J; Liou, S; Liu, J; Liu, X; Maclauchlin, C; Maier, M; Manoharan, M; McDougall, R; Nair, JK; Ramsden, D; Robbie, G; Schmidt, K; Smith, P; Theile, C; Vaishnaw, A; Waldron, S; Wu, JT; Xu, Y; Zhang, X; Zlatev, I | 1 |
| Schuppan, D; Stölzel, U | 1 |
| Anderson, KE; Ávila, MA; Deybach, JC; Fontanellas, A | 1 |
8 review(s) available for acetylgalactosamine and Porphyrias, Hepatic
| Article | Year |
|---|---|
RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
Topics: Acetylgalactosamine; Adolescent; Adult; Heme; Humans; Incidence; Porphobilinogen Synthase; Porphyria, Acute Intermittent; Porphyrias, Hepatic; Pyrrolidines; Quality of Life; RNAi Therapeutics | 2022 |
Givosiran for the treatment of acute hepatic porphyria.
Topics: Acetylgalactosamine; Humans; Porphobilinogen Synthase; Porphyrias, Hepatic; Porphyrins; Pyrrolidines; Quality of Life; RNA, Small Interfering | 2022 |
Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy.
Topics: Acetylgalactosamine; Adult; Humans; Porphobilinogen Synthase; Porphyrias, Hepatic; Pyrrolidines; Quality of Life; RNA, Messenger; RNA, Small Interfering | 2022 |
Givosiran: First Approval.
Topics: 5-Aminolevulinate Synthetase; Acetylgalactosamine; Drug Approval; Enzyme Inhibitors; Humans; Porphobilinogen Synthase; Porphyrias, Hepatic; Pyrrolidines; RNA, Messenger | 2020 |
Givosiran: A Review in Acute Hepatic Porphyria.
Topics: 5-Aminolevulinate Synthetase; Acetylgalactosamine; Acute Kidney Injury; Chemical and Drug Induced Liver Injury; Drug Interactions; Hemin; Hospitalization; Humans; Pain; Porphobilinogen Synthase; Porphyria, Acute Intermittent; Porphyrias, Hepatic; Pyrrolidines; Randomized Controlled Trials as Topic; RNA, Small Interfering; Severity of Illness Index | 2021 |
Development of siRNA Therapeutics for the Treatment of Liver Diseases.
Topics: Acetylgalactosamine; Amyloid Neuropathies, Familial; Animals; Gene Transfer Techniques; Humans; Liver Diseases; Porphyrias, Hepatic; Pyrrolidines; RNA Interference; RNA, Small Interfering; RNAi Therapeutics | 2021 |
The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of
Topics: Acetylgalactosamine; Asialoglycoprotein Receptor; Hepatocytes; Humans; Porphyrias, Hepatic; RNA, Small Interfering | 2022 |
Current and innovative emerging therapies for porphyrias with hepatic involvement.
Topics: 5-Aminolevulinate Synthetase; Acetylgalactosamine; alpha-MSH; Bone Marrow Transplantation; Cholestyramine Resin; Genetic Therapy; Heme; Humans; Liver; Liver Transplantation; Porphyrias, Hepatic; Porphyrins; Pyrrolidines; Receptor, Melanocortin, Type 1 | 2019 |
2 trial(s) available for acetylgalactosamine and Porphyrias, Hepatic
| Article | Year |
|---|---|
A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
Topics: 5-Aminolevulinate Synthetase; Acetylgalactosamine; Adult; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Activation; Female; Humans; Liver; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Omeprazole; Porphyrias, Hepatic; Pyrrolidines; RNA, Small Interfering | 2021 |
Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.
Topics: Acetylgalactosamine; Humans; Porphyria, Acute Intermittent; Porphyrias, Hepatic; Pyrrolidines; Quality of Life | 2022 |
3 other study(ies) available for acetylgalactosamine and Porphyrias, Hepatic
| Article | Year |
|---|---|
Givosiran to treat acute porphyria.
Topics: Acetylgalactosamine; Adolescent; Adult; Child; Humans; Porphyria, Acute Intermittent; Porphyrias, Hepatic; Pyrrolidines; United States | 2021 |
Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved
Topics: 5-Aminolevulinate Synthetase; Acetylgalactosamine; Animals; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Half-Life; Injections, Subcutaneous; Intestinal Elimination; Macaca fascicularis; Male; Models, Animal; Porphobilinogen Synthase; Porphyrias, Hepatic; Pyrrolidines; Rats; Renal Elimination; Tissue Distribution | 2021 |
[New therapeutic option for acute hepatic porphyrias].
Topics: 5-Aminolevulinate Synthetase; Acetylgalactosamine; Humans; Porphobilinogen Synthase; Porphyrias, Hepatic; Pyrrolidines; Randomized Controlled Trials as Topic; RNA, Small Interfering; RNAi Therapeutics | 2021 |